Citius Reports LYMPHIR Revenue Growth and Explores CAR-T Combination

What happened

Citius Pharmaceuticals reported $7.1 million in LYMPHIR revenue for the first nine months of fiscal 2026, with a 77% gross margin. Data showed an 86% overall response rate in a Phase 1 trial combining LYMPHIR with CAR-T for diffuse large B-cell lymphoma, and a 24% ORR in gynecologic malignancies. July saw a record 383 vials ordered, though cash stood at $17.0 million.

Why it matters

The company is expanding beyond its approved CTCL indication, but its $17.0 million cash balance and high operating expenses require accelerated institutional uptake to sustain operations before accessing additional capital.